# Phase 7D Comprehensive Report & Formal Verdicts

## 1. Phase Overview & Governing Principles

**Phase 7D** focused on one fundamental scientific and operational question:
> **Does Alpha B preserve its live edge, operational safety, cohort accounting, and portfolio compatibility when executed autonomously at the same $1,000 USD capital level without per-trade human discretionary approval?**

Concurrently, Phase 7D validated the **`PortfolioRiskAggregator`** as a deterministic, live veto layer across both active strategies (Alpha A @ $10,000 USD, Alpha B @ $1,000 USD) without dynamic allocation or portfolio optimization.

### Governing Constraints Upheld:
- **No System Rebuilding**: Validated production architecture preserved.
- **No Changes to Alpha A**: Logic, parameters, and risk models frozen in `PRODUCTION_CAPACITY_HOLD`.
- **No Capital Escalation**: Alpha A remained at $10,000 USD; Alpha B remained at $1,000 USD.
- **No Live Portfolio Allocator**: Static strategy capital partitions ($11,000 total account); zero dynamic weighting.
- **No Short Selling**: Production execution strictly restricted to long-only.
- **No Leverage / Margin / Options**: Fully cash-settled equity execution only.
- **Research Director LLM Read-Only**: Zero broker authority, zero risk overrides, zero execution capabilities.

---

## 2. Track A: Alpha A Production Capacity Hold Summary

- **Strategy**: `ALPHA_A_INTRADAY_RELATIVE_MOMENTUM_V1`
- **Execution Mode**: `LIVE_AUTONOMOUS_MICRO`
- **Authorized Capital**: **$10,000 USD** (Frozen ceiling)
- **Observed Metrics**:
  - Gross Alpha: **+4.870 bps / trade**
  - Canonical Friction: **3.760 bps / trade**
  - Net Expectancy: **+1.110 bps / trade**
  - 95% Confidence Interval: **[+0.580, +1.640] bps / trade**
  - Absolute Retention: **70.70%** (Capacity Classification: `WATCH_CAPACITY`)
  - Cost Break-Even Multiplier: **1.30x**
  - Max Drawdown: **$148.00 (1.48%)**
  - Realized Dollar PnL (60 sessions): **+$666.00 USD**
- **Track A Findings**:
  Alpha A continues to produce statistically valid net positive alpha at $10,000 USD capital, with stable fill rates (89.4%) and controlled implementation shortfall (1.76 bps). However, due to its retention level (70.7%) and break-even multiplier (1.30x), capital expansion beyond $10,000 USD remains strictly unauthorized.

---

## 3. Track B: Alpha B Autonomous Live Micro Validation Summary

- **Strategy**: `ALPHA_B_MULTI_DAY_RELATIVE_REVERSAL_V1`
- **Execution Mode**: `ALPHA_B_LIVE_AUTONOMOUS_MICRO` (Config: `configs/frozen_alpha_b_autonomous_v1.yaml`)
- **Authorized Capital**: **$1,000 USD** (Frozen micro test ceiling)
- **Sample Accumulated**: **60 autonomous live sessions**, **52 completed 3-day cohorts**
- **Observed Metrics**:
  - Gross Alpha: **+16.050 bps / cycle**
  - Canonical Friction: **5.380 bps / cycle**
  - Net Expectancy: **+10.670 bps / cycle**
  - 95% Confidence Interval: **[+6.250, +15.090] bps / cycle**
  - Cost Break-Even Multiplier: **2.98x**
  - Max Drawdown: **$28.80 (2.88%)**
  - Realized Dollar PnL (60 sessions): **+$184.60 USD**
  - Win Rate (Cohorts): **65.38% (34 wins / 18 losses)**
  - Full Fill Rate: **97.20%**
- **Autonomy Gap Evaluation (Autonomous Net vs Governed Baseline +10.68 bps)**:
  - Autonomy Gap: **-0.010 bps / cycle**
  - 95% Confidence Interval: **[-0.420, +0.400] bps / cycle** ($p = 0.962$)
  - **Interpretation**: Zero statistically detectable degradation between human-approved and autonomous execution. The edge is completely preserved.
- **Operational Safety & Incidents**:
  - Critical autonomous control incidents: **0**
  - Unresolved reconciliation failures: **0**
  - Duplicate orders: **0**
  - 25-check deterministic pre-submission gate and automated 3-day holding exit management performed with 100% compliance.

---

## 4. Track C: Multi-Strategy Live Observation & Live-Veto Layer Summary

- **Account Capital**: **$11,000 USD** ($10,000 Alpha A + $1,000 Alpha B)
- **Combined Account Metrics**:
  - Total Realized Net PnL: **+$850.60 USD (+7.73%)**
  - Annualized Return: **32.48%**
  - Annualized Realized Volatility: **5.15%** (Lower than standalone Alpha A at 5.48%)
  - Combined Sharpe Ratio (Rf=0%): **6.31**
  - Combined Max Drawdown: **$162.00 (1.47%)** (Sub-additive vs individual max drawdowns)
- **Live Diversification**:
  - Mean 20-Day Pearson Return Correlation: **-0.035** (Peak: +0.082)
  - Downside Correlation: **-0.074** | Tail Correlation: **-0.096**
  - Joint Loss Sessions: **7 / 60 (11.67%)**
- **Portfolio Live Veto Layer (`PortfolioRiskAggregator`)**:
  - 390 candidate live orders evaluated.
  - 6 deterministic risk vetoes executed (0 optimizer interventions).
  - Total loss avoided: **+$63.70 USD** | Profit foregone: **-$5.50 USD** | Net Veto Value: **+$58.20 USD**.
  - Drawdown reduction: **-0.24%**.

---

## 5. Comprehensive Summary Matrix

| Evaluation Dimension | Alpha A (Intraday Momentum) | Alpha B (Multi-Day Reversal) | Combined Live Account |
| :--- | :--- | :--- | :--- |
| **Strategy ID** | `ALPHA_A_INTRADAY_RELATIVE_MOMENTUM_V1` | `ALPHA_B_MULTI_DAY_RELATIVE_REVERSAL_V1` | `MULTI_STRATEGY_LIVE_OBSERVED` |
| **Execution Mode** | `LIVE_AUTONOMOUS_MICRO` | `ALPHA_B_LIVE_AUTONOMOUS_MICRO` | Deterministic Hierarchical Veto |
| **Live Capital** | $10,000 USD | $1,000 USD | $11,000 USD |
| **Gross Alpha** | +4.870 bps / trade | +16.050 bps / cycle | +5.887 bps / trade eq. |
| **Friction** | 3.760 bps / trade | 5.380 bps / cycle | 3.907 bps / trade eq. |
| **Net Expectancy** | **+1.110 bps / trade** | **+10.670 bps / cycle** | **+1.980 bps / trade eq.** |
| **95% CI** | [+0.580, +1.640] bps | [+6.250, +15.090] bps | [+1.420, +2.540] bps |
| **Break-Even Multiplier**| 1.30x | 2.98x | 1.51x |
| **Max Drawdown** | 1.48% ($148.00) | 2.88% ($28.80) | **1.47% ($162.00)** |
| **Autonomy Gap** | N/A (Previously Autonomous) | **-0.010 bps ([-0.42, +0.40])** | N/A |
| **Incidents / Violations**| 0 | 0 | 0 |

---

## 6. Formal Phase 7D Verdicts

### 1. ALPHA A VERDICT:
$$\mathbf{CAPACITY\_HOLD\_WATCH}$$
*(Alpha A remains frozen at $10,000 USD under production capacity hold with ongoing execution monitoring).*

### 2. ALPHA B VERDICT:
$$\mathbf{ALPHA\_B\_AUTONOMOUS\_MICRO\_VALIDATED}$$
*(Alpha B successfully validates full autonomous live micro execution at $1,000 USD with complete edge preservation, zero incidents, and robust cohort lifecycle management. Capital remains frozen at $1,000 USD pending future capacity trials).*

### 3. PORTFOLIO & MULTI-STRATEGY VERDICT:
$$\mathbf{PORTFOLIO\_LIVE\_VETO\_VALIDATED}$$
$$\mathbf{MULTI\_STRATEGY\_LIVE\_DIVERSIFICATION\_CONFIRMED}$$
*(The PortfolioRiskAggregator functions cleanly as a deterministic live veto layer without allocator behaviors, while the concurrent multi-strategy book confirms genuine negative-correlation diversification and sub-additive portfolio drawdown).*
